An Open-Label Study to Evaluate Retreatment With LIPO-202
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Salmeterol (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions; Registrational
- Sponsors Neothetics
- 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Mar 2015 According to a media release, Neothetics conducted an end-of-PhaseII meeting with the U.S. FDA in order to establish LIPO-202 phase III development program.
- 25 Mar 2015 New trial record